Corvus Pharmaceuticals, Inc. CRVS

Rank #2300 · Nasdaq · $0.8B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

25.3

P/E

-31.2

P/B

15.03

ROE

-48.2%

Op. Margin

–%

Debt Ratio

65%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -31.2x, P/B 15.03x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -48.2%. Ranks in the top 88% of the universe.

Safety ★★★★☆

Good

Debt ratio 65%. Ranks in the top 28% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2016	–	$-0.0B	$-0.0B	$-0.0B	–	-2377
2017	–	$-0.0B	$-0.0B	$-0.0B	–	-4622
2018	–	$-0.0B	$-0.0B	$-0.0B	–	-32
2019	–	$-0.1B	$-0.1B	$0.1B	–	6
2020	–	$-0.0B	$-0.0B	$0.1B	–	15
2021	–	$-0.0B	$-0.0B	$0.1B	–	17
2023	–	$-0.0B	$-0.0B	$0.1B	–	17
2024	–	$-0.0B	$-0.0B	$0.1B	–	7
2025	–	$-0.0B	$-0.0B	$0.1B	–	65

← See the full screener